These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9553657)

  • 41. Breast cancer subtypes: morphologic and biologic characterization.
    Masood S
    Womens Health (Lond); 2016 Jan; 12(1):103-19. PubMed ID: 26756229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How American oncologists treat breast cancer: an assessment of the influence of clinical trials.
    Belanger D; Moore M; Tannock I
    J Clin Oncol; 1991 Jan; 9(1):7-16. PubMed ID: 1985172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.
    Vogl SE
    Breast Cancer Res Treat; 2017 Nov; 166(1):1-13. PubMed ID: 28695299
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants.
    Kleer CG; van Golen KL; Merajver SD
    Breast Cancer Res; 2000; 2(6):423-9. PubMed ID: 11250736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer and leukemia group B breast committee: decades of progress and plans for the future.
    Hudis CA; Winer EP
    Clin Cancer Res; 2006 Jun; 12(11 Pt 2):3576s-80s. PubMed ID: 16740788
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C; Keam SJ
    Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
    McDaniel RE; Maximov PY; Jordan VC
    Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Metastatic breast cancer: what are the objectives?].
    Salvini P; Ripa C; Ginanni V
    Tumori; 2000; 86(5 Suppl 1):S22-8. PubMed ID: 11195289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
    Bertelsen L; Bernstein L; Olsen JH; Mellemkjaer L; Haile RW; Lynch CF; Malone KE; Anton-Culver H; Christensen J; Langholz B; Thomas DC; Begg CB; Capanu M; Ejlertsen B; Stovall M; Boice JD; Shore RE; ; Bernstein JL
    J Natl Cancer Inst; 2008 Jan; 100(1):32-40. PubMed ID: 18159070
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
    National Institutes of Health Consensus Development Panel
    J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Progress in breast cancer treatment over a quarter of a century].
    Tominaga T
    Gan To Kagaku Ryoho; 1999 Jun; 26 Suppl 1():99-109. PubMed ID: 10410664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. European oncologists' preferences for the management of breast cancer: case presentations and expert commentary.
    Anderssona M; Awadab A; Barrett-Leec P; Ellisd P; Hupperetse P; Jackischf C; Kubistag E; Lückh HJ; Monnerati C; Nitzj U; Untchl M
    Breast; 2008 Feb; 17 Suppl 2():S1-S12. PubMed ID: 18439963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Better prioritization may speed approval of adjuvant therapies in breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2008 Jun; 100(12):842-4. PubMed ID: 18544735
    [No Abstract]   [Full Text] [Related]  

  • 56. Translational research in breast cancer.
    Toi M; Takebayashi Y; Chow LW
    Breast Cancer; 2005; 12(2):86-90. PubMed ID: 15858437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).
    Paluch-Shimon S; Pagani O; Partridge AH; Abulkhair O; Cardoso MJ; Dent RA; Gelmon K; Gentilini O; Harbeck N; Margulies A; Meirow D; Pruneri G; Senkus E; Spanic T; Sutliff M; Travado L; Peccatori F; Cardoso F
    Breast; 2017 Oct; 35():203-217. PubMed ID: 28822332
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
    Del Mastro L; Clavarezza M; Venturini M
    Cancer Treat Rev; 2007 Dec; 33(8):681-7. PubMed ID: 17850976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.